#USA #Minneapolis #Claros Technologies #PFAS Destruction #Bachem AG

Claros Technologies Expands Operations into Europe with Innovative PFAS Destruction Technology

Claros Technologies, a frontrunner in permanent PFAS destruction solutions, has unveiled the success of its commercial-scale pilot project with Bachem AG at their Swiss facility in Bubendorf. This notable achievement signifies the company's strategic expansion into the European pharmaceutical manufacturing landscape, addressing environmental concerns associated with per- and polyfluoroalkyl substances (PFAS).

The pilot tested the ClarosTechUV™ PFAS Destruction System over two weeks, where it met or surpassed the performance standards set by Bachem, a global leader in peptide and oligonucleotide active pharmaceutical ingredients (APIs). Bachem is renowned for producing crucial medications like semaglutide, commonly utilized in therapies for weight management and type 2 diabetes, making this partnership especially significant.

Michelle Bellanca, the CEO and Co-Founder of Claros Technologies, emphasized the importance of this collaboration, stating that it represents a pivotal moment not only for Claros but also for the pharmaceutical sector at large. As the landscape of pharmaceutical manufacturing evolves, there is an increasing need to address the challenge posed by ultra-short-chain PFAS, such as Trifluoroacetic acid (TFA). With Bachem at the forefront of this effort, the integration of the cutting-edge ClarosTechUV™ system underscores a commitment to sustainable practices in pharmaceutical production.

The ClarosTechUV™ system employs an advanced, low-footprint high-flow UV photochemical process designed to efficiently obliterate PFAS contaminants directly at the source. This technology stands in stark contrast to traditional treatment methods, which typically segregate PFAS into secondary waste that necessitates further management and disposal. By allowing manufacturers to integrate PFAS destruction capabilities into existing wastewater structures, ClarosTechUV™ addresses both environmental and regulatory challenges concurrently.

Bachem's decision to adopt ClarosTechUV™ aligns with the mounting regulatory scrutiny surrounding TFA in both Europe and the United States. Authorities are scrutinizing PFAS substances, leading to potential restrictions and monitoring requirements. Bachem’s proactive approach in deploying this technology not only reinforces its social responsibility but also positions it ahead of prospective stringent regulations, ensuring the continued production of vital pharmaceuticals while safeguarding environmental standards.

According to reports from the Swiss newspaper Volksstimme, after treatment with ClarosTechUV™, Bachem detected only minimal residual concentrations of TFA in its industrial wastewater. This notable reduction illustrates the efficacy of the new technology and Bachem’s commitment to reducing environmental impact.

André Casagrande, Site Manager at Bachem’s Bubendorf facility, illustrated the company’s ethos by stating, "We strive to innovate while remaining environmentally responsible. Our goal is not just to produce effective medications but to ensure that our manufacturing processes contribute positively to the world around us."

The ongoing partnership between Claros Technologies and Bachem reflects a broader trend towards environmentally accountable manufacturing in pharmaceuticals. As Bachem continues to meet rising demands for peptide therapeutics and rapidly evolving medical treatments, their collaboration with Claros will be pivotal in shaping a more sustainable production framework.

In summary, Claros Technologies is not merely expanding its operations; it is redefining standards in the pharmaceutical industry. By tackling TFA and other PFAS chemicals head-on, Claros positions itself as a leader in the sustainable manufacturing movement within pharmaceuticals, ensuring that ethical practices are integral to business strategies.

For continued innovation and responsible production in the pharmaceutical sector, the industry can look forward to the promising contributions of Claros Technologies and Bachem AG as they pave the way towards eco-conscious manufacturing solutions.

• ---

About Claros Technologies

Founded in 2018 and headquartered in Minneapolis, Claros Technologies specializes in delivering innovative PFAS destruction systems designed for various applications, including industrial and municipal wastewater treatment. With a mission to eliminate the persistent nature of harmful chemicals, Claros Technologies is pushing the boundaries of environmental responsibility in industrial practices.

About Bachem AG

Bachem AG, known for its innovation in delivering peptide and oligonucleotide APIs, has over five decades of experience in the pharmaceutical sector. With a dedication to quality and sustainability, Bachem continues to lead the industry in developing essential medical products while enhancing their environmental stewardship.